Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Revenue (2021 - 2025)

Historic Revenue for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $180.9 million.

  • Kiniksa Pharmaceuticals International's Revenue rose 6116.97% to $180.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $598.0 million, marking a year-over-year increase of 5568.24%. This contributed to the annual value of $423.2 million for FY2024, which is 5660.5% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Revenue stood at $180.9 million for Q3 2025, which was up 6116.97% from $156.8 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Revenue peaked at $180.9 million during Q3 2025, and registered a low of -$148.3 million during Q4 2022.
  • For the 5-year period, Kiniksa Pharmaceuticals International's Revenue averaged around $67.6 million, with its median value being $75.7 million (2023).
  • Examining YoY changes over the last 5 years, Kiniksa Pharmaceuticals International's Revenue showed a top increase of 71963.62% in 2022 and a maximum decrease of 89112.3% in 2022.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Revenue (Quarter) stood at $18.7 million in 2021, then crashed by 891.12% to -$148.3 million in 2022, then surged by 156.24% to $83.4 million in 2023, then surged by 46.93% to $122.5 million in 2024, then soared by 47.59% to $180.9 million in 2025.
  • Its Revenue stands at $180.9 million for Q3 2025, versus $156.8 million for Q2 2025 and $137.8 million for Q1 2025.